FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
FibroBiologics (Nasdaq: FBLG) announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2024 Cell & Gene Meeting on the Mesa Conference in Phoenix, Arizona, on October 7, 2024. The presentation will focus on updates regarding the company's pre-clinical IND-enabling studies in chronic wound healing and psoriasis, as they prepare for a phase I/II diabetic foot ulcer (DFU) clinical trial with their CYWC628 topically administered fibroblast spheroid product candidate.
Dr. Khoja emphasized the company's approach of leveraging the regenerative potential of fibroblasts for tissue repair and immune modulation. FibroBiologics aims to create innovative cell-based approaches for treating chronic diseases. The presentation is scheduled for 5:45 p.m. MST in the FLW Ballroom F.
FibroBiologics (Nasdaq: FBLG) ha annunciato che il Chief Scientific Officer, Hamid Khoja, Ph.D., presenterà al 2024 Cell & Gene Meeting on the Mesa Conference a Phoenix, Arizona, il 7 ottobre 2024. La presentazione si concentrerà sugli aggiornamenti riguardanti gli studi pre-clinici abilitanti l'IND in tema di guarigione delle ferite croniche e psoriasi, mentre si preparano per un trial clinico di fase I/II per ulcere del piede diabetico (DFU) con il loro prodotto candidato a base di fibroblasti sferoidi CYWC628.
Il Dott. Khoja ha sottolineato l'approccio dell'azienda di sfruttare il potenziale rigenerativo dei fibroblasti per la riparazione dei tessuti e la modulazione immunitaria. FibroBiologics mira a creare approcci innovativi basati sulle cellule per il trattamento delle malattie croniche. La presentazione è programmata per le 17:45 MST nella FLW Ballroom F.
FibroBiologics (Nasdaq: FBLG) anunció que el Director Científico, Hamid Khoja, Ph.D., presentará en la 2024 Cell & Gene Meeting on the Mesa Conference en Phoenix, Arizona, el 7 de octubre de 2024. La presentación se centrará en las actualizaciones sobre los estudios preclínicos que habilitan la IND en la curación de heridas crónicas y psoriasis, mientras se preparan para un ensayo clínico de fase I/II para úlceras del pie diabético (DFU) con su producto candidato de esferoides de fibroblastos CYWC628 administrado tópicamente.
El Dr. Khoja enfatizó el enfoque de la compañía de aprovechar el potencial regenerativo de los fibroblastos para la reparación de tejidos y la modulación inmunitaria. FibroBiologics tiene como objetivo crear enfoques innovadores basados en células para el tratamiento de enfermedades crónicas. La presentación está programada para las 5:45 p.m. MST en el FLW Ballroom F.
FibroBiologics (Nasdaq: FBLG)는 최고 과학 책임자 Hamid Khoja, Ph.D.가 2024 Cell & Gene Meeting on the Mesa Conference에 참석해 발표할 것이라고 발표했습니다. 행사 장소는 미국 애리조나주 피닉스이며, 발표일자는 2024년 10월 7일입니다. 이번 발표는 회사의 만성 상처 치유 및 건선에 대한 임상 전 IND 지원 연구 업데이트에 집중할 것이며, CYWC628 외용 섬유 아세포 구형 제품 후보를 사용할 제1/2상 당뇨병성 발 궤양(DFU) 임상 시험을 준비하고 있습니다.
Khoja 박사는 조직 복구 및 면역 조절을 위한 섬유 아세포의 재생 잠재력을 활용하는 회사의 접근 방식을 강조했습니다. FibroBiologics는 만성 질환 치료를 위한 혁신적인 세포 기반 접근 방식을 개발하는 것을 목표로 하고 있습니다. 발표는 오후 5:45 MST에 FLW Ballroom F에서 예정되어 있습니다.
FibroBiologics (Nasdaq: FBLG) a annoncé que le directeur scientifique, Hamid Khoja, Ph.D., présentera lors de la 2024 Cell & Gene Meeting on the Mesa Conference à Phoenix, Arizona, le 7 octobre 2024. La présentation portera sur les mises à jour concernant les études précliniques d'autorisation d'IND sur la cicatrisation des plaies chroniques et le psoriasis, alors qu'ils se préparent pour un essai clinique de phase I/II sur les ulcères du pied diabétique (DFU) avec leur produit candidate de sphéroïdes fibroblastes CYWC628 administré localement.
Le Dr Khoja a souligné l'approche de l'entreprise consistant à tirer parti du potentiel régénératif des fibroblastes pour la réparation des tissus et la modulation immunitaire. FibroBiologics vise à créer des approches cellulaires innovantes pour traiter les maladies chroniques. La présentation est prévue pour 17h45 MST dans la FLW Ballroom F.
FibroBiologics (Nasdaq: FBLG) gab bekannt, dass der Chief Scientific Officer, Hamid Khoja, Ph.D., auf der 2024 Cell & Gene Meeting on the Mesa Conference in Phoenix, Arizona, am 7. Oktober 2024 präsentieren wird. Die Präsentation wird sich auf Updates zu den präklinischen IND-erforderlichen Studien zur Heilung chronischer Wunden und Psoriasis konzentrieren, während sie sich auf eine klinische Studie der Phase I/II zu diabetischen Fußgeschwüren (DFU) mit ihrem topisch verabreichten Fibroblastensphäroid-Produkten CYWC628 vorbereiten.
Dr. Khoja betonte den Ansatz des Unternehmens, das regenerative Potenzial von Fibroblasten für die Gewebereparatur und Immunmodulation zu nutzen. FibroBiologics zielt darauf ab, innovative zellbasierte Ansätze zur Behandlung chronischer Erkrankungen zu entwickeln. Die Präsentation ist für 17:45 Uhr MST im FLW Ballroom F angesetzt.
- None.
- None.
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs
HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2024 Cell & Gene Meeting on the Mesa Conference taking place October 7-9 in Phoenix, Arizona.
“We always look forward to attending this very informative and collaborative meeting. For this year’s meeting we will present an update of our pre-clinical IND-enabling studies in chronic wound healing and psoriasis as we prepare for a phase I/II diabetic foot ulcer (DFU) clinical trial with our CYWC628 topically administered fibroblast spheroid product candidate,” said Dr. Khoja. “Our approach focuses on leveraging the regenerative potential of fibroblasts, which play a crucial role in tissue repair and immune modulation. By advancing these potential therapeutics to the clinic, we aim to create new and innovative cell-based approaches for treating chronic diseases.”
Details of the presentations are as follows:
Event: 2024 Cell & Gene Meeting on the Mesa
Session Date and Time: October 7, 2024, at 5:45 p.m. MST
Location: FLW Ballroom F
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning potential product candidates, including expected research targets and indications of interest, plans for, and the timing of, clinical trials, and FibroBiologics’ ability to create new and innovative cell-based approaches for treating chronic diseases. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.fibrobiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What will FibroBiologics (FBLG) present at the 2024 Cell & Gene Meeting on the Mesa?
When and where is FibroBiologics (FBLG) presenting at the 2024 Cell & Gene Meeting on the Mesa?
What is the focus of FibroBiologics' (FBLG) research presented at the 2024 Cell & Gene Meeting on the Mesa?
What is FibroBiologics' (FBLG) CYWC628 product candidate?
